GSK-3 alpha: Small Molecules and Peptides
GSK-3 is a Ser/Thr kinase first identified as an inactivator of Glycogen Synthase. GSK-3 acts as a multifunctional downstream switch that determines the output of numerous signaling pathways. There are two mammalian GSK-3 isoforms encoded by distinct genes, GSK-3 alpha and GSK-3 beta, which are structurally similar, but functionally non-identical. GSK-3a is inhibited by phosphorylation at S21 by Akt and other kinases. GSK-3 alpha and GSK-3 beta share 85% amino acid identity. Dysregulated GSK-3 has been implicated in several diseases including type II diabetes, Alzheimers disease, bipolar disorder, and cancer.
13 results for "GSK-3 alpha Small Molecules and Peptides" in Products
13 results for "GSK-3 alpha Small Molecules and Peptides" in Products
GSK-3 alpha: Small Molecules and Peptides
GSK-3 is a Ser/Thr kinase first identified as an inactivator of Glycogen Synthase. GSK-3 acts as a multifunctional downstream switch that determines the output of numerous signaling pathways. There are two mammalian GSK-3 isoforms encoded by distinct genes, GSK-3 alpha and GSK-3 beta, which are structurally similar, but functionally non-identical. GSK-3a is inhibited by phosphorylation at S21 by Akt and other kinases. GSK-3 alpha and GSK-3 beta share 85% amino acid identity. Dysregulated GSK-3 has been implicated in several diseases including type II diabetes, Alzheimers disease, bipolar disorder, and cancer.
Highly selective GSK-3 inhibitor; acts as Wnt activator
| Alternate Names: | CHIR99021,CT99021 |
| Chemical Name: | 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile |
| Purity: | ≥98% |
CHIR 99021 synthesized to cGMP guidelines
| Chemical Name: | 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile |
| Purity: | ≥99% |
Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitor
| Alternate Names: | CT99021 |
| Chemical Name: | 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile trihydrochloride |
| Purity: | ≥98% (HPLC) |
Sterile-filtered 10 mM solution of CHIR 99021 pre-dissolved in DMSO
| Chemical Name: | 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile |
| Purity: | ≥97% (HPLC) |
Potent, selective GSK-3 inhibitor
| Chemical Name: | 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione |
| Purity: | ≥98% (HPLC) |
Potent GSK3 Degrader (PROTAC®)
| Chemical Name: | 3-Amino-6-(4-((4-(4-(1-(17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazol-4-yl)butyl)piperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
Potent, selective GSK-3 inhibitor
| Chemical Name: | 3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione |
| Purity: | ≥98% (HPLC) |
Highly potent and selective GSK-3 inhibitor
| Chemical Name: | N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine |
| Purity: | ≥98% (HPLC) |
Selective GSK-3 inhibitor
| Chemical Name: | N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea |
| Purity: | ≥98% (HPLC) |
Highly potent, selective GSK-3 inhibitor
| Chemical Name: | 1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea |
| Purity: | ≥98% (HPLC) |
Highly potent GSK-3 inhibitor; inhibits tau phosphorylation
| Chemical Name: | 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide |
| Purity: | ≥98% (HPLC) |
Wnt pathway inhibitor
| Chemical Name: | 4-[4-(4-Methoxyphenyl)-5-[[[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methyl]thio]-4H-1,2,4-triazol-3-yl]-pyridine |
| Purity: | ≥98% (HPLC) |
Inactive isomer of GSK J1 (Cat. No. 4593)
| Chemical Name: | N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine ethyl ester |
| Purity: | ≥98% (HPLC) |
